Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states
Project Number7U19AI158076-03
Former Number5U19AI158076-03
Contact PI/Project LeaderVAN OPIJNEN, TIM Other PIs
Awardee OrganizationBOSTON CHILDREN'S HOSPITAL
Description
Abstract Text
SUMMARY
Deployment of new antimicrobials is promptly circumvented by the rapid evolution of resistance, underscoring
the critical need for new strategies to stay ahead in the arms-race against bacterial pathogens. Developing a
detailed understanding of the circumstances as well as genetic and mechanistic basis for which antibiotic
resistance develops provides opportunities for pre-emptively subverting this process. While infections caused by
organisms harboring antimicrobial resistance (AMR) genes are a major cause of antibiotic treatment failure (ATF),
ATF frequently occurs when the etiological agents are not AMR by traditional susceptibility testing. It is becoming
increasingly recognized that transient cell-states such as tolerance, persistence and hetero-resistance are critical
drivers underlying treatment failure. However, there is a paucity of data with regards to the genetic and
mechanistic basis for these cell-states as well as a lack of diagnostic-detection approaches. ATF cell-states
initially exist as minority variants within a population and display a transient phenotype that tends to dissipate as
the stress subsides, making them challenging to detect and consequently missed in current diagnostic assays.
These enabler cell-states remain mechanistically poorly understood and seem to preferentially arise during
fluctuating treatment regimens, for instance caused by a drug’s PK/PD characteristics, whereby ATF cell-states
can drive the re-emergence of the (susceptible) bacterial infection after antibiotic pressure wanes. Importantly,
this creates opportunities where multi-step high-level resistance mutations are given an extended opportunity to
emerge. Therefore, because antibiotic resistant variants often follow closely on the heels of the occurrence of
ATF cell-states, these cell-states can be viewed as enablers of antibiotic treatment failure and AMR. This
proposal focuses on untangling the importance of ATF cell-states in the emergence of antibiotic
resistance and treatment failure, and designs new approaches and strategies to identify, track and target
them. The main team consists of 4 principal investigators that have a very successful collaboration history.
Together they will work on 5 challenges distributed across 3 projects and supported by an administrative and a
genomics and bioinformatics core. In Challenge: 1) the full profile of possible genetic pathways that can induce
ATF cell-states is determined; 2) treatment regimens that drive the emergence of ATF-cell states are determined;
3) it is determined how ATF cell-states enable the emergence of AMR; 4) drugs and compounds are screened
for, that target ATF cell-state collateral sensitivities; 5) a computational deconvolution approach is developed
that predicts the presence and frequency of ATF cell-states in a complex bacterial population. Overall this
proposal contains a collection of conceptually and technically innovative aspects that are geared towards
understating the genetic mechanisms and evolutionary forces that sit at the root of the emergence of resistance,
with the ultimate goal to design new diagnostics and antimicrobial strategies that can slow or even stop the
current endless arms-race “that takes all the running we can do, to keep in the same place”.
Public Health Relevance Statement
NARRATIVE
The current arms-race that exists between drug discovery and the bacterial pathogens that rapidly develop
resistance against these new antibiotics can be ended by interfering with the key evolutionary processes that
enable resistance to emerge. Herein, we untangle the importance of the cell-states of tolerance, persistence and
hetero-resistance in their roles as harbingers of antibiotic treatment failure (ATF) and enablers of resistance. We
identify the treatment regimens that select for ATF cell-state induction, uncover the genetic mechanisms
underlying their emergence, devise strategies to target their collateral sensitivities, and develop a proof-of-
principle computational diagnostics approach that predicts the presence and frequency of ATF cell-states in
complex bacterial populations.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
076593722
UEI
Z1L9F1MM1RY3
Project Start Date
12-September-2022
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$2,588,682
Direct Costs
$1,999,012
Indirect Costs
$589,670
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$2,588,682
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7U19AI158076-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7U19AI158076-03
Patents
No Patents information available for 7U19AI158076-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7U19AI158076-03
Clinical Studies
No Clinical Studies information available for 7U19AI158076-03
News and More
Related News Releases
No news release information available for 7U19AI158076-03
History
No Historical information available for 7U19AI158076-03
Similar Projects
No Similar Projects information available for 7U19AI158076-03